US 7,442,838 B2
	Polymorphic forms of sertraline hydrochloride
Paul Adriaan Van Der Schaaf, Hagenthal-le-Haut (France); Franz Schwarzenbach, Frenkendorf (Switzerland); Hans Jürg Kirner, Pratteln (Switzerland); Martin Szelagiewicz, Münchenstein (Switzerland); Claudia Marcolli, Zürich (Switzerland); and Andreas Burkhard, Basel (Switzerland)
Assigned to Ciba Specialty Chemicals Corp., Tarrytown, N.Y. (US)
Filed on Apr. 08, 2005, as Appl. No. 11/101,860.
Application 11/101860 is a continuation in part of application No. 10/736195, filed on Dec. 15, 2003, granted, now 6,939,992.
Application 10/736195 is a continuation of application No. 10/111947, granted, now 6,872,853, previously published as PCT/EP00/10416, filed on Oct. 23, 2000.
Claims priority of application No. 99810981 (EP), filed on Oct. 29, 1999.
Prior Publication US 2005/0197404 A1, Sep. 08, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 211/42 (2006.01)

U.S. Cl. 564—308

9 Claims

1. A process for the preparation of sertraline hydrochloride polymorphic form II, wherein hydrogen chloride is added to a solution of sertraline free amine in a ketone selected from the group consisting of acetone, methyl ethyl ketone, and methyl isobutyl ketone wherein sertraline hydrochloride polymorphic form II is crystallized out of said solution.